Skip to main content

March 2020, Vol 10, No 3

Zanubrutinib (Brukinsa), a novel Bruton tyrosine kinase (BTK) inhibitor—which was approved by the FDA in November 2019 for the treatment of mantle-cell lymphoma—achieved high overall response rate (ORR) and durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those with high-risk cytogenetics, according to findings presented at ASH 2019.

Read Article ›

Engaging in advocacy is one of the key responsibilities of patient and nurse navigators, according to Elizabeth Franklin, MSW, from the Cancer Support Community.

Read Article ›

The American Society of Clinical Oncology (ASCO) recently released a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to enable all oncology practices to deliver higher-­quality care at lower cost. The update comes more than 5 years after ASCO released its first model and incorporates feedback from medical oncologists in diverse practice settings, as well as practice administrators, payer representatives, and experts in physician payment and business analysis.

Read Article ›

Ensuring health literacy is not just about giving patients health information, it is also making sure they’re understanding it, processing it, and able to take action on the information they’ve been given.

Read Article ›

There is a growing recognition among payers and providers that social determinants of health—the social and socioeconomic factors that influence a patient’s care, such as income and access to transportation—are strongly linked to health outcomes. This recognition has been reinforced by a shift toward value-based payments, which incentivizes improved health outcomes rather than service delivery alone. Although it is evident that mitigating adverse social determinants can have a positive impact on patient outcomes and curb spending, results from a recent study reveal that Accountable Care Organizations (ACOs) face substantial challenges in integrating social services with patient care (Murray GF, et al. Health Aff (Millwood). 2020;39:199-206).

Read Article ›

Almost 50% of patients with chronic lymphocytic leukemia (CLL) who received treatment with the triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) as first-line therapy achieved undetectable minimal residual disease (MRD) in the bone marrow after only 8 monthly cycles of therapy, according to data presented at ASH 2019.

Read Article ›

An investigational oral form of azacitidine (CC-486) as maintenance therapy induced a statistically significant improvement in overall survival (OS) compared with placebo in patients with newly diagnosed acute myeloid leukemia (AML) who achieved a complete response or complete response with incomplete hematologic recovery after treatment with induction chemotherapy.

Read Article ›

The combination of duvelisib (Copiktra) plus venetoclax (Venclexta) is a promising all-oral regimen for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Read Article ›

The combination of the BCL2 inhibitor venetoclax (Venclexta) and intensive chemotherapy has demonstrated notable results in fit patients with newly diagnosed or relapsed or refractory acute myeloid leukemia (AML), according to results from a phase 1b/2 single-center clinical trial presented at ASH 2019.

Read Article ›

A potent, oral small-molecule bromodomain and extraterminal domain (BET) inhibitor—CPI-0610—improves spleen volume and symptoms when added to the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) in ruxolitinib-­naïve patients with myelofibrosis. Ruxolitinib is the only FDA-approved treatment for myelofibrosis.

Read Article ›

Page 1 of 2